Is BPC-157 legal now? What the Oct 28, 2026 HHS peptide policy does and does not allow

Last updated: November 2, 2026. On October 28, 2026, the Department of Health and Human Services released a draft enforcement discretion policy on compounding with six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The Federal Register printed its notice of availability on October 30, 2026 (91 FR 68526, document 2026-22192) and describes the document as a draft. If it stood as written it would change the federal enforcement picture for these six substances. It does not approve them, it does not make them available to buy, and the notice states that it is not binding on HHS or the public.

This page walks through what the policy says, in the order people ask about it. Every claim below comes from the HHS policy, the Federal Register notice, or FDA’s own pages, and the sources are listed at the end.

The short answer

• Did something change on Oct 28, 2026? A draft policy changed, not a rule. In it HHS said it does not intend to take enforcement action against a State-licensed pharmacy, Federal facility or licensed physician compounding with these six peptides when specific conditions are met. The Federal Register notice calls the document a draft and says it is not binding on HHS or the public.
• Is BPC-157 FDA approved now? No. Nothing was approved. Compounded drugs are not FDA-approved, as the HHS document itself states.
• Is BPC-157 on the 503A bulks list? No. The draft is an interim enforcement position while that list is developed through rulemaking.
• Can I buy it online? No. The draft policy covers compounding by a pharmacy from a bulk substance, on a patient-specific prescription, under conditions. It is not a consumer purchase route.
• Comments close two weeks after the October 30, 2026 publication date, through regulations.gov on Docket No. HHS-OASH-2026-0496.

Is BPC-157 legal?

Legal is not one question. Three separate things have to line up: whether a prescriber can lawfully write for it, whether a pharmacy can lawfully compound it, and whether you can lawfully buy it on your own.

The draft October 28 policy addresses the second one. In it HHS wrote that, until a peptide bulk drug substance is addressed in a final rule as being included or not included on the 503A bulks list, it “does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance” listed in Appendix A of the policy, when all of the conditions in the policy are present.

That is an enforcement position, in the same family as FDA’s other interim compounding policies, and it is a draft rather than a final rule. It tells pharmacies and physicians what the federal government will not prioritize prosecuting. It does not create a right, and the Federal Register notice says so in plain words: the policy “does not establish any rights for any person and is not binding on HHS or the public.”

Two more limits matter. A state board can still restrict what its licensees do, and the policy does not touch state law. And the product still has to be compounded for a specific patient under a valid prescription, because that requirement is built into section 503A and the policy restates it as a condition.

Can compounding pharmacies make BPC-157 and TB-500 now?

On the federal side, the draft says a pharmacy that meets every condition in the policy would not be a target of enforcement action on these six substances. If it stands, that is a change worth understanding, because before April 2026 the same substances sat in FDA’s Category 2, the tier for bulk substances that may present significant safety risks.

The timeline is useful here. BPC-157 and KPV were placed in Category 2 in September 2023, and TB-500, Epitalon, MOTS-c and Semax on September 29, 2023. FDA’s Category 2 page, which the agency dates April 22, 2026, now lists them in a separate table headed “Bulk drug substances nominated but withdrawn,” and FDA’s safety write-up for each one is still published on that page. HHS’s policy describes the same fact: each substance “was in Category 2 from September 2023 until April 22, 2026, and neither the placement nor the removal changed their status under section 503A.”

So the sequence is: not Category 2 anymore as of April 22, 2026, not on the 503A bulks list either, and since October 28, 2026 described in a draft federal enforcement discretion policy that is open for comment and is not binding. A pharmacy that compounds one of these six still has to satisfy the conditions list below, and its state board of pharmacy still has a say.

Is it FDA approved?

No. Not BPC-157, not TB-500, not any of the six, and not compounded drugs generally. The HHS document says it directly: “Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed.”

FDA approval is a different process entirely. It means the agency reviewed a specific manufacturer’s application for a specific drug product and cleared it for sale. None of that happened here. What happened is narrower: an advisory committee reviewed the substances for compounding eligibility, and HHS then released a draft statement about enforcement while the bulks list is developed by rulemaking.

One more distinction people miss. Being on the 503A bulks list would not make a substance approved either. The list settles one question, whether a pharmacy may use that ingredient when compounding, and nothing else.

What conditions apply?

Ten circumstances decide whether a compounded product is inside the policy, and all of them have to be present. Closely paraphrased:

1. Interim access list. The peptide bulk drug substance appears in Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax or TB-500.
2. Identity and route. It has the identity and the route-of-administration limits described in Appendix B, including amino acid sequence, chemical structure, molecular weight and molecular formula.
3. Characterization. The bulk substance comes from a facility registered under section 510 and is identified in a valid certificate of analysis, with test results consistent with FDA’s guidance-based criteria, so identity, purity, potency and contaminants such as endotoxins, heavy metals, microbial contamination and impurities are tested rather than assumed.
4. Manufacturer, not just a reseller. The original manufacturer, not a later packer, repacker, labeler or distributor, is registered with FDA under section 510, complies with current good manufacturing practice, and its physical location is listed on the certificate of analysis. If the substance came through a registered repacker or reseller, that entity documented its own vendor validation.
5. Reporting. The compounder reports serious adverse events and product quality issues to FDA’s MedWatch program and to the states where the products are compounded and sent, and reports the active ingredient and strength per unit, the original manufacturer with its facility identifier, and the dosage form and route.
6. Labeling. The label carries the statement: “This is a compounded drug product. Not for resale.”
7. Single ingredient. The product contains only one active pharmaceutical ingredient from Appendix A. No stacking two of the six in one vial.
8. Route. If the peptide is compounded in an oral dosage form, the compounder is expected to keep documentation confirming that the specific formulation achieves adequate oral bioavailability in humans.
9. Device. The only drug delivery device co-packaged with or containing the product is an FDA 510(k)-cleared syringe.
10. Everything else still applies. The product complies with the rest of the Food, Drug, and Cosmetic Act, including not being compounded under insanitary conditions and the section 503A patient-specific prescription requirement.

Two of those conditions decide whether a supply chain is inside the policy. Condition 4 rules out the anonymous bulk supply chain, because a certificate of analysis has to name a real FDA-registered manufacturer and its location. Condition 7 rules out combination vials, which is exactly the format a lot of gray-market sellers prefer.

Which routes does the policy name, peptide by peptide?

In the draft, Appendix B attaches a route limit to each substance. Where the policy names a salt form, the table keeps it, because the policy does.

Appendix A substances and the dosage forms named in Appendix B

Peptide	Form named in Appendix B	Routes the policy describes
BPC-157	BPC-157 acetate	Subcutaneous, intramuscular, oral and topical dosage forms
TB-500	TB-500 acetate	Subcutaneous or intramuscular injectable dosage forms
Epitalon	Epitalon acetate	Subcutaneous or intramuscular injectable dosage forms, dispensed in intermittent courses
Semax	Semax free base	Intranasal use
KPV	KPV acetate	Topical and oral dosage forms
MOTS-c	MOTS-c acetate	Subcutaneous or intramuscular injectable dosage forms

Nothing in that table is medical advice, and route language in a policy document is not a dosing instruction. It tells you what a compounder may do and still stay inside the policy. Semax, for example, is described for intranasal use only, so an injectable Semax product is outside the description even though Semax itself is on the list.

What the policy is not

• Not an approval. No peptide was approved, and the policy says compounded drugs are not FDA-approved.
• Not a listing. None of the six is on the 503A bulks list, and the policy exists because that list is still being developed through rulemaking.
• Not permanent. HHS wrote that it “may revisit application of this interim policy (in whole or in part) if, among other things, a safety signal or product quality issue arises with a compounded drug product within the scope of this policy.”
• Not binding, and not final. The Federal Register notice describes the document as a draft, states that it is not binding on HHS or the public, and creates no rights.
• Not a shield from state boards. The policy is federal. State boards of pharmacy and medicine set their own rules for their licensees, and the policy does not change state law.
• Not a change to anything else. Substances outside Appendix A, and combination products with more than one of the six, are outside this policy.

What about research-use-only peptides?

The policy is blunt about its target. HHS wrote that it intends the policy to “discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients,” and that by allowing limited compounding under safeguards, the policy “provides patients with a more controlled alternative.”

The “research use only, not for human consumption” vial is the target of the policy, not an exemption from it. The label on those vials is a seller’s disclaimer, not a regulatory category, and the policy’s answer is a compounded product with a named manufacturer, a certificate of analysis and a prescription, which is a different supply chain with different paperwork.

If a seller cites the October 28 policy to justify shipping you a research vial, that is a misreading at best. The policy describes what a pharmacy may compound and what it must document, and it applies to pharmacies, federal facilities and physicians, not to online storefronts.

How to check a pharmacy

Ask for these in writing before you pay.

1. Which pharmacy, and what type? A 503A pharmacy compounds for an identified patient on a prescription. A 503B outsourcing facility operates under different federal rules. The name and type should be in writing before you pay.
2. Can they show the certificate of analysis? Under the policy it should name the original manufacturer, the facility location, and test results. If nobody will show you one, the product is outside the conditions.
3. Is the label statement there? “This is a compounded drug product. Not for resale.” should be on the labeling.
4. One ingredient or several? The policy covers single-ingredient products from Appendix A. A blended vial of two or more of the six is outside it.
5. Which route? The route on the paperwork should match the route in Appendix B for that peptide.
6. What exactly will this cost? A written total, including the consult, the compound and any dispensing or shipping charge, before you commit.

For the state-level half of the check, look up the pharmacy’s license on your state board of pharmacy’s own site rather than trusting a page that also sells the product. Our verification methodology explains how we handle listing data and what we do not claim about it, and our directory of peptide clinics by metro area currently includes 653 compounding pharmacies among its 1,941 listings, counted from the directory data page on October 28, 2026. Every one of those listings carries a “license not verified” flag, because we publish from public business records and let each business confirm its own details. Use them as a starting list to check, not as a substitute for the check.

What happens next

Comments on the policy are open until two weeks after the October 30, 2026 Federal Register publication date, through regulations.gov on Docket No. HHS-OASH-2026-0496. FDA’s future rulemakings may propose adding some or all of these peptides to the 503A bulks list based on the available evidence, and HHS has said it may revisit the policy if a safety or quality signal appears.

Until a final rule lands, the accurate way to describe these six peptides is: not FDA-approved, not on the 503A bulks list, no longer in Category 2 as of April 22, 2026, and described in a draft federal enforcement discretion policy released October 28, 2026, noticed in the Federal Register on October 30, that would apply only when all ten conditions are met.

Sources

• HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A and Appendix B and the testing standard table.
• Federal Register, 91 FR 68526, October 30, 2026, FR Doc. 2026-22192, Docket No. HHS-OASH-2026-0496.
• FDA, Bulk drug substances that may present significant safety risks, content current as of 04/22/2026, including the “nominated but withdrawn” table.
• FDA, Bulk Drug Substances Used in Compounding Under Section 503A.

Frequently asked questions

This page is informational. It is not medical advice, it does not recommend any product or dose, and it does not tell you whether any treatment is right for you. Find Peptide Clinics does not sell peptides.

Related: BPC-157 FDA status and what US law allows · all compound status guides.